Evidence map›Paper›PMID 17653584›Full record

ArticleWorld journal of surgery2007

Reversal of diabetes in mice by intrahepatic injection of bone-derived GFP-murine mesenchymal stem cells infected with the recombinant retrovirus-carrying human insulin gene.

Jian Xu, Yuhua Lu, Fei Ding, Xi Zhan, Mingyan Zhu, Zhiwei Wang

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of surgery, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Stem cell-derived islet cells for transplantation.Current opinion in organ transplantation · 2011
    Review
  15. Article
  16. Gene therapy in diabetes.Self/nonself · 2010
    Article
  17. Review
  18. Stem cells as a therapeutic target for diabetes.Frontiers in bioscience (Landmark edition) · 2010
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jian XuDepartment of General Surgery, the Affiliated Hospital, Nantong University, Nantong, Jiangsu Province, China, 226001.
Yuhua LuDepartment of General Surgery, the Affiliated Hospital, Nantong University, Nantong, Jiangsu Province, China, 226001.
Fei DingKey Laboratory of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China, 226001.
Xi ZhanGreenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore, USA.
Mingyan ZhuDepartment of General Surgery, the Affiliated Hospital, Nantong University, Nantong, Jiangsu Province, China, 226001.
Zhiwei WangDepartment of General Surgery, the Affiliated Hospital, Nantong University, Nantong, Jiangsu Province, China, 226001. dxjqhy@yahoo.com.cn.
Nantong University · CNAffiliated Hospital of Nantong University · CNUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe objective of this study was to assess the effect of intrahepatic injection of bone-derived green fluorescent protein (GFP)-transgenic murine mesenchymal stem cells (GFP-mMSCs) containing the human insulin(ins) gene in streptozotocin-induced diabetic mice.

methodsGFP-mMSCs were isolated from the bone marrow of GFP transgenic mice, expanded, and transfected with a recombinant retrovirus MSCV carrying the human insulin gene. C57BL/6J mice were made diabetic by an intraperitoneal administration of 160 mg/kg streptozotocin (STZ), followed by intrahepatic injection of transfected GFP-mMSCs. The variations in body weight and the blood glucose and serum insulin levels were determined after cell transplantation. GFP-mMSCs survival and human insulin expression in liver tissues were examined by fluorescent microscopy and immunohistochemistry.

resultsThe body weight in diabetic mice that received GFP-mMSCs harboring the human insulin gene was increased by 6% within 6 weeks after treatment, and the average blood glucose levels in these animals were 10.40 +/- 2.80 mmol/l (day 7) and 6.50 +/- 0.89 mmol/l (day 42), respectively, while the average values of blood glucose in diabetic animals without treatment were 26.80 +/- 2.49 mmol/l (day 7) and 25.40 +/- 4.10 mmol/l (day 42), showing a significant difference (p < 0.05). Moreover, secretion of human insulin of GFP-mMSCs in serum and animal liver was detected by radioimmunoassay (RIA) and immunohistochemistry (IHC).

conclusionsExperimental diabetes could be relieved effectively for up to 6 weeks by intrahepatic transplantation of murine mesenchymal stem cells expressing human insulin. This study implies a novel approach of gene therapy for type I diabetes.

Indexed as

LiverMesenchymal Stem Cell TransplantationAnimalsBone and BonesDiabetes Mellitus, ExperimentalDisease Models, AnimalGenetic TherapyGenetic VectorsGreen Fluorescent ProteinsHumansHypoglycemic AgentsInjectionsInsulinMiceMice, Inbred C57BLMice, TransgenicGreen Fluorescent ProteinsHypoglycemic AgentsInsulin

Identifiers

PMID17653584
OpenAlexW2032032556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.